Back

Stress adaptation pathways and HA-CD44 signaling maintain the survival of pancreatic cancer cells with centrosome amplification

Ozcan, S. C.; Goksel, E.; Kalkan, B. M.; Cicek, E.; Kanevetci, B.; Acilan, C.

2026-01-26 cancer biology
10.64898/2026.01.24.701523 bioRxiv
Show abstract

Centrosome amplification (CA) is a hallmark of aggressive cancers, including pancreatic ductal adenocarcinoma (PDAC), and is linked to genomic instability and poor prognosis. While CA promotes tumor evolution, it also imposes substantial intracellular stress that cells must overcome to survive. However, the specific metabolic adaptations that enable cancer cells to tolerate stress induced by supernumerary centrosomes remain poorly understood. Here, we show that PDAC cells with CA acquire distinct metabolic dependencies that sustain survival. A metabolism-focused CRISPR-Cas9 screen, coupled with functional validations, identified critical vulnerabilities in three inter-connected axes: redox homeostasis, nucleotide sugar metabolism, and the unfolded protein response (UPR). Specifically, CA elevates intracellular reactive oxygen species (ROS), creating a reliance on glutamine metabolism and NRF2-driven antioxidant signaling. CRISPR screen hits in the hexosamine and uronic acid pathways revealed dependencies that converge on hyaluronic acid (HA) metabolism, and functional assays demonstrated that the HA-CD44 axis is required for centrosome clustering and mitotic fidelity, with its disruption increasing lethal multipolar divisions. In parallel, CA activated all branches of the UPR, and both hyper-activation and suppression of ER stress proved detrimental, indicating a finely tuned proteostatic equilibrium is essential for adaptation. Together, these findings show that, in a PLK4-driven model, centrosome-amplified cells rely on coordinated redox control, proteostatic buffering, and extracellular matrix signaling to tolerate CA-induced stress, revealing selective vulnerabilities that could be therapeutically exploited to target aggressive, therapy-resistant tumor subpopulations.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 19%
9.9%
2
Cell Reports
1338 papers in training set
Top 4%
8.2%
3
Developmental Cell
168 papers in training set
Top 3%
6.7%
4
Cancer Discovery
61 papers in training set
Top 0.3%
6.2%
5
EMBO Molecular Medicine
85 papers in training set
Top 0.4%
4.2%
6
Cell Metabolism
49 papers in training set
Top 0.4%
3.9%
7
Cancer Research
116 papers in training set
Top 0.7%
3.8%
8
Molecular Cell
308 papers in training set
Top 4%
3.5%
9
Oncogene
76 papers in training set
Top 0.5%
3.5%
10
Nature Cancer
35 papers in training set
Top 0.3%
3.5%
50% of probability mass above
11
Cell Death & Disease
126 papers in training set
Top 0.4%
3.5%
12
Cancer Cell
38 papers in training set
Top 0.6%
2.7%
13
Cell Death & Differentiation
48 papers in training set
Top 0.1%
2.7%
14
Advanced Science
249 papers in training set
Top 8%
2.5%
15
Gastroenterology
40 papers in training set
Top 0.8%
2.3%
16
Nature Cell Biology
99 papers in training set
Top 2%
2.3%
17
Science Advances
1098 papers in training set
Top 13%
2.0%
18
Journal of Clinical Investigation
164 papers in training set
Top 2%
1.8%
19
Nature Metabolism
56 papers in training set
Top 1%
1.7%
20
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 33%
1.7%
21
Nature Genetics
240 papers in training set
Top 5%
1.5%
22
The EMBO Journal
267 papers in training set
Top 3%
1.2%
23
eLife
5422 papers in training set
Top 50%
1.2%
24
Immunity
58 papers in training set
Top 3%
0.9%
25
Genome Medicine
154 papers in training set
Top 7%
0.9%
26
Cell Reports Medicine
140 papers in training set
Top 7%
0.8%
27
Nature
575 papers in training set
Top 16%
0.7%
28
Cell
370 papers in training set
Top 18%
0.7%
29
Journal of Experimental Medicine
106 papers in training set
Top 4%
0.7%
30
Gut
36 papers in training set
Top 1%
0.6%